18 independently detected trends connected to this subject, with the latest coverage first.
This hub groups 18 separate news trends connected to Semaglutide, spanning June 20, 2026 through October 14, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 143 article observations and 134 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
10 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
5 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Some who take GLP-1s are suffering serious side effects, but it's unclear how often.
9 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Weight lost on GLP‑1 drugs often returns faster than it vanished, sparking a new debate on lasting obesity treatment.
Weight-loss drugs not working as expected lead to withdrawal-like cravings and unexpected side effects.
A childhood‑obesity drug once reserved for adults now shows weight‑loss promise in kids as young as six.
Recent findings show late-life semaglutide treatment slows ageing and extends lifespan in female mice.
GLP-1 medications, known for weight loss, are now being studied for their potential to treat addictions.
A national trial is exploring whether GLP-1s, known for weight loss, can also help with alcohol use disorder.
New research suggests that popular weight-loss drugs may work differently than previously understood.
A new application for weight-loss drugs is being explored to treat alcohol use disorder
Nearly 200 deaths in the UK have been linked to popular weight-loss drugs Ozempic and Mounjaro, raising urgent questions about their safety.
Researchers investigating 6,000 existing medications have identified potential links between common drugs and slowed biological aging.
Novo Nordisk has entered into a partnership with Vivani to develop a long-acting semaglutide implant designed for weight management.
New study data suggests GLP-1 medications like Ozempic and Wegovy may reduce fracture risks and improve bone health in Type 2 diabetes patients.